Compare · TRIL vs UROV
TRIL vs UROV
Side-by-side comparison of Trillium Therapeutics Inc. (TRIL) and Urovant Sciences Ltd. (UROV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TRIL and UROV operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TRIL carries a market cap of $1.94B.
- TRIL has more recent analyst coverage (5 ratings vs 0 for UROV).
- Company
- Trillium Therapeutics Inc.
- Urovant Sciences Ltd.
- Price
- $19.30-3.45%
- -
- Market cap
- $1.94B
- -
- 1M return
- -3.79%
- -
- 1Y return
- -5.02%
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2018
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 0
Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Latest TRIL
- Defiance ETFs Announces Closure of Select Funds
- Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets
- Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
- 10 Psychedelics CEOs To Pay Attention To In 2022
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
- SEC Form 15-12B filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company
- SEC Form 4 filed by Pucci Paolo
Latest UROV
- Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
- Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg
- Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
- SEC Form 15-12B filed by Urovant Sciences Ltd.
- SEC Form EFFECT filed by Urovant Sciences Ltd.
- SEC Form 4: E. Bryan Smith disposed to the issuer $0 worth of Common Shares (124,447 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Sef Kurstjens disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: M. James Hindman disposed to the issuer $0 worth of Common Shares (9,000 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Cornelia Haag-Molkenteller disposed to the issuer $0 worth of Common Shares (141,348 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Ajay Bansal disposed to the issuer $0 worth of Common Shares (140,098 units at $0.00), decreasing direct ownership by 100% to 0 units